Humana's antitrust claims against '97,500%' Mallinckrodt price hike advance

Antitrust claims filed by Humana against Mallinckrodt over price hikes the pharmaceutical company made on an anti-inflammatory drug can advance, a federal judge said Aug. 14.

In a lawsuit filed in August of last year, Humana accused Mallinckrodt of partaking in "one of the most outrageous price-gouging schemes in the history of American medicine" with its anti-inflammatory drug Acthar Gel. Humana alleged that a vial of Acthar cost $40 in 2001, but its cost grew to $39,000 by 2018, or by 97,500 percent.

When the lawsuit was filed, Mallinckrodt told Becker's in a statement that it "strongly believes that Humana's complaint is completely without merit" and "that the complaint should be dismissed in its entirety."

Federal Judge Dale Fischer of Los Angeles declined to grant Mallinckrodt's motion to dismiss the lawsuit in its entirety, though granted dismissal of some parts of the suit. According to his Aug. 14 order, Mr. Fischer said Humana's antitrust claims against Mallinckrodt can advance.

Subscribe to the following topics: humanamallinckrodt

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy.
 

Articles We Think You'll Like

 

Thank you so much for your interest in our content. Please register to access this complimentary archived content. By registering, you will receive our newsletter which can be opted out of at any time.

 

 

Already Registered? Click here to confirm.